Imagine trying to fight a fire without knowing if your extinguisher actually works. This effort gathers doctors and scientists globally to test which medicines really stop the mpox virus and how it spreads. By sharing data from different countries, they create a playbook for treating patients and preparing for future outbreaks.
Pharmaceutical companies and health agencies lack high-quality, randomized evidence on which antiviral drugs actually work against different clades of the mpox virus, leading to inefficient patient management and regulatory delays.
A global clinical research network that produced the MOSAIC cohort for disease characterization and three randomized clinical trials (UNITY, EPOXI, MOSA) to test antiviral efficacy.
If you are a drug developer dealing with uncertain efficacy data for mpox treatments — this project developed a network of randomized clinical trials (RCTs) that provides pooled Individual Participant Data Meta-Analysis. This allows you to understand why certain drugs, like tecovirimat, may not reduce lesion resolution time.
If you are a hospital operator dealing with inconsistent patient management protocols during an epidemic — this project developed clinical characterization protocols based on the MOSAIC cohort. This ensures your staff uses the most current evidence for treating severe cases.
If you are a health agency dealing with slow response times to new virus clades — this project developed a rapid-response trial design and data-sharing system across 9 countries. This helps you update public health policies and guidelines faster during a PHEIC.
Based on available project data, there is no specific pricing or cost information provided for the protocols or trial designs.
The project already operates at a significant scale, involving 17 partners across 9 countries and enrolling 480 participants in the UNITY trial alone.
Based on available project data, specific licensing terms are not mentioned, though the project emphasizes data-sharing across global studies.
The EPOXI trial was specifically designed to fulfill EMA requirements for treatment authorization, although it was halted in summer 2025.
The project runs from 2022-08-05 to 2026-08-04, with some findings already published in Clinical Infectious Diseases in early 2025.
The consortium is heavily weighted toward research and academia, with 7 universities and 6 research institutes. Industrial presence is very low at 6% (1 company), suggesting the project's primary goal is clinical validation and public health policy rather than immediate commercial product development. The geographic spread across 9 countries, including South America and Africa, provides a strong global footprint for clinical data collection.
Contact the Institut National de la Santé et de la Recherche Médicale (INSERM) in France.
Contact us to access the pooled Individual Participant Data Meta-Analysis for antiviral efficacy.
